Jefferies Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Jefferies Group’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-171,300	Closed	-$6.45M	–	2191
2021 Q1	$6.45M	Buy	171,300 +150,700	+732%	+$3.76M	0.06%	303
2020 Q4	$350K	Buy	+20,600	New	+$258K	﹤0.01%	1241
2019 Q2	–	Sell	-14,300	Closed	-$192K	–	3018
2019 Q1	$192K	Hold	14,300	–	–	﹤0.01%	1959
2018 Q4	$133K	Buy	+14,300	New	+$170K	﹤0.01%	1923
2016 Q4	–	Sell	-25,500	Closed	-$1.34M	–	2593
2016 Q3	$1.34M	Hold	25,500	–	–	0.01%	1136
2016 Q2	$1.05M	Buy	+25,500	New	+$1.11M	﹤0.01%	1129

Jefferies Group's FPRX Position: Q2 2021 in Review

Jefferies Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 18,132 shares — an estimated $683K sold.

Jefferies Group first reported a position in FPRX in Q2 2016 and held it in 8 quarters. The position peaked at $683K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Jefferies Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 18,132 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $683K.
Jefferies Group first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 8 quarters.
Jefferies Group's Five Prime Therapeutics, Inc. position peaked at $683K in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.